Ultragenyx Pharma (RARE) Misses Q4 EPS by 45c

Ultragenyx Pharma (NASDAQ: RARE) reported Q4 EPS of ($1.79), $0.45 worse than the analyst estimate of ($1.34). Revenue for the quarter came in at $83.4 million versus the consensus estimate of $83.79 million.

GUIDANCE:

The company expects 2022 revenue for Crysvita in Ultragenyx territories to be between $250 million and $260 million and Dojolvi revenue to be between $55 million and $65 million.

For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c
• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c